Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case -3% Improvement Relative Risk Metformin for COVID-19  Farah et al.  Prophylaxis Does metformin reduce COVID-19 infections? Retrospective 1,039 patients in Jordan No significant difference in cases c19early.org Farah et al., J. Int. Medical Research, Sep 2023 Favors metformin Favors control

Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study

Farah et al., Journal of International Medical Research, doi:10.1177/03000605231198413
Sep 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now known with p < 0.00000000001 from 88 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Retrospective 1,039 diabetes patients in Jordan, showing no significant difference in COVID-19 cases with metformin use in unadjusted results. Severity outcomes are not provided for metformin.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of case, 2.7% higher, RR 1.03, p = 0.87, treatment 267 of 821 (32.5%), control 69 of 218 (31.7%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Farah et al., 20 Sep 2023, retrospective, Jordan, peer-reviewed, mean age 59.5, 10 authors. Contact: r.farah@ju.edu.jo.
This PaperMetforminAll
Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study
Randa I Farah, Hussam Al-Hawari, Asma Albtoush, Amani Nofal, Tala Basheer Hyasat, Raghed Abdel Hay Abu Jabeh, Lojayn Tareq Suboh, Ahmad A Toubasi, Tareq Fatah Eqrai, Mohammad Abufaraj
Journal of International Medical Research, doi:10.1177/03000605231198413
Objectives: The clinical course of coronavirus disease 2019 (COVID-19) infection is often aggressive, with unfavorable outcomes for those with comorbidities such as type 2 diabetes mellitus (T2DM). We aimed to assess the prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with COVID-19 infection who had T2DM. Methods: In this cross-sectional study, we included adult patients with T2DM who attended an endocrinology clinic and underwent testing for COVID-19 infection. Results: Among 1039 included patients, the mean age was 59.5 AE 11.0 years and 429 (41.3%) were men. Overall, 87.1% of patients had received COVID-19 vaccination and 32.3% had confirmed COVID-19 infection. The COVID-19-related mortality was 3.0% and rate of post-COVID-19 lung fibrosis was 19.1%. Vaccination was associated with lower COVID-19-related
Authors' contributions Randa I. Farah contributed to study conceptualization; formal analysis; methodology; supervision; and original writing, drafting, review, and editing of the manuscript. Hussam Al-Hawari contributed to study supervision and editing, Declaration of conflicting interests The authors declare that there is no conflict of interest.
References
Abdi, Jalilian, Sarbarzeh, Diabetes and COVID-19: a systematic review on the current evidence, Diabetes Res Clin Pract, doi:10.1016/j.diabres.2020.108347
Antonelli, Penfold, Merino, Risk factors and disease profile of postvaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, casecontrol study, Lancet Infect Dis, doi:10.1016/S1473-3099(21)00460-6
Barron, Bakhai, Kar, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30272-2
Bereda, Dual insulin resistance causes: how frequently type 2 diabetes mellitus and COVID-19 infection caused diabetic ketoacidosis? a case report, Ann Med Surg (Lond), doi:10.1097/MS9.0000000000000341
Brosh-Nissimov, Orenbuch-Harroch, Chowers, BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel, Clin Microbiol Infect, doi:10.1016/j.cmi.2021.06.036
Cariou, Hadjadj, Wargny, Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study, Diabetologia, doi:10.1007/s00125-020-05180-x
Cordero-Franco, De, Garza-Salinas, Gomez-Garcia, Risk factors for SARS-CoV-2 infection, pneumonia, intubation, and death in Northeast Mexico, Front Public Health, doi:10.3389/fpubh.2021.645739
Ejaz, Alsrhani, Zafar, COVID-19 and comorbidities: deleterious impact on infected patients, J Infect Public Health, doi:10.1016/j.jiph.2020.07.014
Faghir-Gangi, Moameri, Abdolmohamadi, The prevalence of type 2 diabetes in patients with COVID-19: a systematic review and meta-analysis, Clin Diabetol, doi:10.5603/DK.2020.0041
Feldman, Savelieff, Hayek, COVID-19 and diabetes: a collision and collusion of two diseases, Diabetes, doi:10.2337/dbi20-0032
Gesesew, Koye, Fetene, Risk factors for COVID-19 infection, disease severity and related deaths in Africa: a systematic review, BMJ Open, doi:10.1136/bmjopen-2020-044618
Gregg, Sophiea, Weldegiorgis, Diabetes and COVID-19: population impact 18 months into the pandemic, Diabetes Care, doi:10.2337/dci21-0001
Harding, Ali, Gander, 174-LB: Diabetes as a risk factor for long-COVID-19: a scoping review, Diabetes, doi:10.2337/db22-174-LB
Hayek, Robert, Matar, Risk factors for hospital admission among COVID-19 patients with diabetes. A study from Saudi Arabia, Saudi Med J, doi:10.15537/smj.2020.10.25419
Jung, Park, Kim, Association between body mass index and risk of coronavirus disease 2019 (COVID-19): a nationwide case-control study in South Korea, Clin Infect Dis, doi:10.1093/cid/ciaa1257
Kumar, Arora, Sharma, Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.04.044
Leon-Abarca, Portmann-Baracco, Alberti, Diabetes increases the risk of COVID-19 in an altitude dependent manner: an analysis of 1,280,806 Mexican patients, PLoS One, doi:10.1371/journal.pone.0255144
Mahmud, Imam, Vinnakota, Vaccination intention against COVID-19 among the unvaccinated in Jordan during the early phase of the vaccination drive: a cross-sectional survey, Vaccines, doi:10.3390/vaccines10071159
Martellucci, Flacco, Soldato, Effectiveness of COVID-19 vaccines in the general population of an Italian region before and during the Omicron wave, Vaccines, doi:10.3390/vaccines10050662
Murillo-Zamora, Trujillo, Huerta, First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence, Public Health, doi:10.1016/j.puhe.2022.04.001
Notarte, Catahay, Velasco, Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review, EClinicalMedicine, doi:10.1016/j.eclinm.2022.101624
Pal, Bhadada, COVID-19 and diabetes mellitus: an unholy interaction of two pandemics, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.04.049
Pal, Sachdeva, Mukherjee, Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: a preliminary report, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.12.035
Raveendran, Misra, Post COVID-19 syndrome ("long COVID") and diabetes: challenges in diagnosis and management, Diabetes Metab Syndr, doi:10.1016/j.dsx.2021.102235
Shahbazi, Solgi, Khazaei, Predisposing risk factors for COVID-19 infection: a case-control study, Caspian J Intern Med, doi:10.22088/cjim.11.0.495
Shang, Shao, Guo, Diabetes mellitus is associated with severe infection and mortality in patients with COVID-19: a systematic review and meta-analysis, Arch Med Res, doi:10.1016/j.arcmed.2020.07.005
Stefan, Birkenfeld, Schulze, Obesity and impaired metabolic health in patients with COVID-19, Nat Rev Endocrinol, doi:10.1038/s41574-020-0364-6
Von Elm, Altman, Egger, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Ann Intern Med
Zhang, Li, Zhang, The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: a singlecentre, retrospective, observational study in Wuhan, Diabetes Obes Metab, doi:10.1111/dom.14086
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit